Key Points
- Director Bruce Cozadd sold 6,000 Jazz Pharmaceuticals shares at an average price of $250.13, generating approximately $1.5 million. The transaction occurred under a pre-arranged Rule 10b5-1 trading plan, leaving him with 351,875 shares.
- Jazz reported quarterly revenue of $1.21 billion, up 15.5% year over year and above estimates, but adjusted EPS of $5.71 missed the $6.18 consensus forecast.
- Analysts remain broadly positive, with a consensus “Buy” rating and an average price target of $285.44; institutional investors own approximately 89.14% of the company’s stock.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) Director Bruce Cozadd sold 6,000 shares of the business's stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $250.13, for a total value of $1,500,780.00. Following the sale, the director owned 351,875 shares of the company's stock, valued at approximately $88,014,493.75. This represents a 1.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jazz Pharmaceuticals Price Performance
Shares of JAZZ opened at $245.57 on Thursday. The business's fifty day moving average is $248.38 and its 200 day moving average is $220.39. Jazz Pharmaceuticals PLC has a 12-month low of $123.88 and a 12-month high of $266.38. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. The stock has a market cap of $15.94 billion, a P/E ratio of 16.94, a P/E/G ratio of 0.22 and a beta of 0.36.
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing analysts' consensus estimates of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.11 billion. During the same quarter last year, the firm posted ($8.25) EPS. The business's revenue for the quarter was up 15.5% compared to the same quarter last year. Sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 21.5 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in JAZZ. California State Teachers Retirement System boosted its holdings in Jazz Pharmaceuticals by 24,585.6% during the second quarter. California State Teachers Retirement System now owns 15,714,136 shares of the specialty pharmaceutical company's stock worth $3,786,635,000 after purchasing an additional 15,650,479 shares during the last quarter. Capital World Investors increased its stake in Jazz Pharmaceuticals by 4.4% in the 4th quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company's stock valued at $453,322,000 after buying an additional 111,735 shares during the last quarter. Ameriprise Financial Inc. lifted its position in shares of Jazz Pharmaceuticals by 11.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company's stock worth $198,159,000 after buying an additional 191,637 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Jazz Pharmaceuticals by 164.0% during the 4th quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company's stock worth $309,215,000 after buying an additional 1,129,995 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Jazz Pharmaceuticals by 44.5% during the 1st quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company's stock worth $317,485,000 after buying an additional 517,514 shares in the last quarter. 89.14% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on the stock. Truist Financial upped their target price on shares of Jazz Pharmaceuticals from $264.00 to $281.00 and gave the stock a "buy" rating in a report on Wednesday, August 26th. Raymond James Financial reiterated an "outperform" rating and set a $239.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Canaccord Genuity Group set a $300.00 price objective on Jazz Pharmaceuticals in a research note on Wednesday, August 26th. Needham & Company LLC increased their price objective on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a "buy" rating in a research note on Wednesday, August 26th. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of Jazz Pharmaceuticals in a report on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $285.44.
Get Our Latest Analysis on JAZZ
Jazz Pharmaceuticals Company Profile
(
Get Free Report)
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.
Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
